Cor Vasa 2018, 60(3):e321-e326 | DOI: 10.1016/j.crvasa.2017.06.012

Heterogeneous aetiology and clinical presentation of cardiac involvement in hypereosinophilic syndrome: A case series

Martin Kotrča,*, Miloš Kubáneka, Pavlína Malíkováb, Dana Kautznerovác, Jacqueline Maaloufd, Tereza Jančuškováe, Petr Lupíneka, Jana Vrbskáa, Vojtěch Melenovskýa, Josef Kautznera
a Klinika kardiologie, Institut klinické a experimentální medicíny, Praha, Česká republika
b Pracoviště laboratorních metod, Institut klinické a experimentální medicíny, Praha, Česká republika
c Pracoviště radiodiagnostiky a intervenční radiologie, Institut klinické a experimentální medicíny, Praha, Česká republika
d Ústav hematologie a krevní transfuze, Praha, Česká republika
e Synlab Genetics, Praha, Česká republika

Introduction: Hypereosinophilic syndrome (HES) is a heterogeneous group of diseases defined by marked hyperesonofilia (1.5× 109/l) that persists more than 6 months with organ infiltration and damage. Cardiac involvement in HES is common and is associated with significant morbidity and mortality. To illustrate contemporary diagnostic and therapeutic methods, we reviewed three cases of HES with cardiac involvement, recently diagnosed in our institution.
Description of cases: We present a series of three cases of HES with cardiac involvement and clinical presentation in the form of intracardiac thrombosis. One of these cases was caused by FIP1L1-PDGFRA positive myeloproliferation and successfully treated with imatinib. All cases received corticosteroids and oral anticoagulation with vitamin K antagonists with favourable clinical outcomes.

Conclusions: Although HES with cardiac involvement is a rare condition, it may have severe clinical consequences and needs to be diagnosed early. Subsequent important step is careful differential diagnosis of hypereosinophilia and its targeted treatment.

Keywords: Eosinophilic myocarditis; Hypereosinophilic; Loeffler endocarditis

Received: November 12, 2016; Revised: June 1, 2017; Accepted: June 23, 2017; Published: June 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotrč M, Kubánek M, Malíková P, Kautznerová D, Maalouf J, Jančušková T, et al.. Heterogeneous aetiology and clinical presentation of cardiac involvement in hypereosinophilic syndrome: A case series. Cor Vasa. 2018;60(3):e321-326. doi: 10.1016/j.crvasa.2017.06.012.
Download citation

References

  1. R. Mankad, C. Bonnichsen, S. Mankad, Hypereosinophilic syndrome: cardiac diagnosis and management, Heart 102 (2016) 100-106. Go to original source... Go to PubMed...
  2. M.M. Crane, C.M. Chang, M.G. Kobayashi, et al., Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence, Journal of Allergy and Clinical Immunology 126 (2010) 179-181. Go to original source... Go to PubMed...
  3. P.U. Ogbogu, B.S. Bochner, J.H. Butterfield, et al., Hypereosinophilic syndromes: a multicenter, retrospective analysis of clinical characteristics and response to therapy, Journal of Allergy and Clinical Immunology 124 (2009) 1319-1325. Go to original source... Go to PubMed...
  4. C. Lefebvre, O. Bletry, P. Degoulet, et al., Prognostic factors of hypereosinophilic syndrome. Study of 40 cases, Annales de Medecine Interne 140 (1989) 253-257.
  5. C.J. Spry, J. Davies, P.C. Tai, et al., Clinical features of fifteen patients with the hypereosinophilic syndrome, Quarterly Journal of Medicine 52 (1983) 1-22.
  6. P. Valent, A.D. Klion, H.-P. Horny, et al., Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes, Journal of Allergy and Clinical Immunology 130 (2012) 607-612.e9. Go to original source... Go to PubMed...
  7. A.D. Klion, J. Robyn, C. Akin, Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome, Blood 103 (2004) 473-478. Go to original source... Go to PubMed...
  8. M.R. Del Bene, F. Cappelli, L. Rega, et al., Characterization of Löeffler eosinophilic myocarditis by means of real time three-dimensional contrast-enhanced echocardiography, Echocardiography 29 (2012) E62-E66. Go to original source... Go to PubMed...
  9. J. Gotlib, J. Cools, J.M. Malone 3rd, et al., FIP1L1-PDGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management, Blood 103 (2004) 2879-2891. Go to original source... Go to PubMed...
  10. C.W. Boustany Jr., G.W. Murphy, G.L. Hicks Jr., Mitral valve replacement in idiopathic hypereosinophilic syndrome, Annals of Thoracic Surgery 51 (1991) 1007-1009. Go to original source... Go to PubMed...
  11. D. Korczyk, G. Taylor, H. McAlistair, et al., Heart transplantation in a patient with endomyocardial fibrosis due to hypereosinophilic syndrome, Transplantation 83 (2007) 514-516. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.